Multimodal AI-driven analysis in breast and lung cancer: insights from the OPTIMA prototyping workshop

This paper reports on insights from the OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial Intelligence) prototyping workshop held in Berlin from November 6 to November 8, 2024. Through integrated analysis of clinical, genomic, imaging and pathology data, we addressed the following key challenges in breast and lung cancer management: utility of comprehensive genomic profiling in metastatic breast cancer settings; relevance of tumor heterogeneity for predicting treatment response; development of less invasive technologies for assessing tumor biology; and treatment outcomes in early stages of small cell lung cancer. Our findings demonstrate the potential of computational analysis using multiple data modalities to identify cancer molecular subtypes and enhance treatment selection and monitoring while highlighting important areas for future development to achieve the research objectives of the OPTIMA consortium.

Authors

Institutions

Publication Details

Journal
BMC Proceedings
Published
2026-04-01
DOI
https://doi.org/10.1186/s12919-026-00370-8
Primary Topic
AI in cancer detection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multimodal AI-driven analysis in breast and lung cancer: insights from the OPTIMA prototyping workshop

Michael Bussmann, Danielle Newby, B. De Meulder, Eng Hooi Tan et al.
BMC Proceedings
AI in cancer detection
article

Multimodal AI-driven analysis in breast and lung cancer: insights from the OPTIMA prototyping workshop

Michael Bussmann, Danielle Newby, B. De Meulder, Eng Hooi Tan, Graeme J. Thorn, Vivek Kumar Singh, Juan Gómez Rivas, Maryam Abdollahyan, Lisa Schneider, Ayman Hijazy, Giorgos Papanastasiou, Asieh Golozar, Óscar Maiques, Philip Cornford, Thomas Abbott, Claude Chelala, L. Stanley James, Javier Cuadrado Corz, Emanuela Gadaleta, Manuel Hettich, Rossella Nicolleti
article en

Abstract

This paper reports on insights from the OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial Intelligence) prototyping workshop held in Berlin from November 6 to November 8, 2024. Through integrated analysis of clinical, genomic, imaging and pathology data, we addressed the following key challenges in breast and lung cancer management: utility of comprehensive genomic profiling in metastatic breast cancer settings; relevance of tumor heterogeneity for predicting treatment response; development of less invasive technologies for assessing tumor biology; and treatment outcomes in early stages of small cell lung cancer. Our findings demonstrate the potential of computational analysis using multiple data modalities to identify cancer molecular subtypes and enhance treatment selection and monitoring while highlighting important areas for future development to achieve the research objectives of the OPTIMA consortium.

BMC ProceedingsVol. 20(S15)
University of Liverpool (GB), Queen Mary University of London (GB), Pfizer (United States) (US), Aintree University Hospitals NHS Foundation Trust (GB), European Association of Urology (NL), Helmholtz-Zentrum Dresden-Rossendorf (DE), Nuffield Orthopaedic Centre (GB), Odyssey House (US), Hospital Clínico San Carlos (ES), University of Oxford (GB), Azienda Ospedaliero-Universitaria Careggi (IT), MNM Consulting (France) (FR), Bayer (Germany) (DE), Ludwig-Maximilians-Universität München (DE)
Openalex Percentile: Top 33%
AI in cancer detection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.